Danaher reported Q2 revenues of $5.94 billion, reflecting a 4% increase year over year and surpassing analyst estimates. Growth was driven primarily by an 8% revenue rise in its biotechnology segment, while diagnostics revenue increased 2%. Core revenues rose 2% overall. Despite a drop in net earnings to $555 million from $907 million in the prior year, adjusted earnings per share of $1.80 beat consensus estimates. The company reaffirmed 3% core revenue growth guidance for 2025 and announced CFO Matthew McGrew’s planned retirement, with Matthew Gugino named as successor effective February 2026.